Business
Aclaris is a clinical-stage biopharmaceutical company developing small and large molecule candidates for immuno-inflammatory diseases.
Aclaris cut its net loss, but revenue and free cash flow worsened as the pipeline shifted deeper into development.
The read at a glance✓ Audited against SEC data
- Business mix — Immuno-inflammatory drug pipelineNote
- Revenue — Revenue -58.2% to $7.8MWatch
- Profitability — Net loss improved to $64.9MOK
- Cash burn — Free cash flow was -$47.2MWatch
- Balance sheet — Equity -33.7% to $103.1MWatch
- Insiders — 0 buys / 1 sellWatch
- Accounting — Altman-Z distress; EQ distressWatch
Where the revenue comes from
Fiscal 2025, as Aclaris Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- License And Service$6.0M
- Dermatology Therapeutics$6.0M
- Laboratory Research Revenue$1.9M
- Contract Research$1.9M
Leadership changes
From Aclaris Therapeutics, Inc.'s own filings, the day they're filed.
- Neal Walker · Chief Executive Officer · departureeff. 2024-11-18
- Andrew Powell · member of the board of directors · departureeff. 2024-03-14
- Bryan Reasons Not · director · departureeff. 2024-03-14
Latest filings
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-04
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aclaris Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.